BB Biotech (BBZA) Stock Statistics & Valuation Metrics
Total Valuation
BB Biotech has a market cap or net worth of EUR 3.04B. The enterprise value is -EUR 433.37M.
- Market Cap
- EUR 3.04B
- Enterprise Value
- -EUR 433.37M
Share Statistics
BB Biotech has 55,149,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 55,149,250
- Owned by Insiders
- ―
- Owned by Institutions
- 2.93%
Financial Efficiency
BB Biotech’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 21.06%.
- Return on Equity (ROE)
- 0.21
- Return on Assets (ROA)
- 0.21
- Return on Invested Capital (ROIC)
- 21.06%
- Return on Capital Employed (ROCE)
- 0.21
- Revenue Per Employee
- 7.68M
- Profits Per Employee
- 57.81M
- Employee Count
- 10
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BB Biotech is 2.63. BB Biotech’s PEG ratio is 0.00.
- PE Ratio
- 2.63
- PS Ratio
- 12.89
- PB Ratio
- 0.87
- Price to FCF
- 14.44
- Price to Operating Cash Flow
- 14.44
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, BB Biotech had revenue of 76.81M and earned 578.13M in profits. Earnings per share was 10.54.
- Revenue
- 76.81M
- Gross Profit
- 76.76M
- Operating Income
- 586.83M
- Pretax Income
- 578.20M
- Net Income
- 578.13M
- EBITDA
- 578.64M
- Earnings Per Share (EPS)
- 10.54
Cash Flow
In the last 12 months, operating cash flow was 195.90M and capital expenditures 0, giving a free cash flow of 195.90M billion.
- Operating Cash Flow
- 195.90M
- Free Cash Flow
- 195.90M
- Free Cash Flow per Share
- 3.55
Dividends & Yields
BB Biotech pays an annual dividend of EUR 2.43, resulting in a dividend yield of 4.35%
- Dividend Per Share
- EUR 2.43
- Dividend Yield
- 4.35%
- Payout Ratio
- 9.22%
- Free Cash Flow Yield
- 6.92%
- Earnings Yield
- 38.05%
Stock Price Statistics
- Beta
- 0.69
- 52-Week Price Change
- 26.19%
- 50-Day Moving Average
- 55.33
- 200-Day Moving Average
- 51.41
- Relative Strength Index (RSI)
- 59.17
- Average Volume (3m)
- 6,649
Important Dates
BB Biotech upcoming earnings date is Jan 22, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 23, 2026
- Next Earnings Date
- Jan 22, 2027
- Ex-Dividend Date
- Mar 23, 2026
Financial Position
BB Biotech as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.17
- Interest Coverage Ratio
- 1324.68
Taxes
In the past 12 months, BB Biotech has paid 66.00K in taxes.
- Income Tax
- 66.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
BB Biotech EV to EBITDA ratio is 2.47, with an EV/FCF ratio of 13.59.
- EV to Sales
- 12.13
- EV to EBITDA
- 2.47
- EV to Free Cash Flow
- 13.59
- EV to Operating Cash Flow
- 13.59
Balance Sheet
BB Biotech has EUR 3.30B in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 3.30B billion.
- Cash & Marketable Securities
- EUR 3.30B
- Total Debt
- EUR 0.00
- Net Cash
- EUR 3.30B
- Net Cash Per Share
- EUR 59.76
- Tangible Book Value Per Share
- EUR 59.10
Margins
Gross margin is 100.00%, with operating margin of 490.68%, and net profit margin of 490.56%.
- Gross Margin
- 100.00%
- Operating Margin
- 490.68%
- Pretax Margin
- 490.59%
- Net Profit Margin
- 490.56%
- EBITDA Margin
- 490.59%
- EBIT Margin
- 490.59%
Analyst Forecast
The average price target for BB Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 129.76%
- EPS Growth Forecast
- 542.43%
